FDA issues EUA for J&J’s single-dose COVID-19 vaccine

Editor's Note

The Food and Drug Administration (FDA) on February 27 issued an emergency use authorization (EUA) for Johnson & Johnson’s single-dose COVID-19 vaccine, making it the third coronavirus vaccine approved for use in the US.

The vaccine can be administered to people ages 18 and older. Vaccinations will begin as soon as states receive the doses. Four million doses are expected to go out within a week, and 20 million doses are expected to become available by the end of March.

Studies found that the vaccine, developed by Janssen Biotech Inc, a Janssen Pharmaceutical Company of Johnson & Johnson, was approximately 67% effective in preventing moderate to severe/critical COVID-19 occurring at least 14 days after vaccination and 66% effective at 28 days.

In addition, the vaccine was approximately 77% effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85% at 28 days.